Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope
for a protective immunization. Renewed optimism in this area of research comes in part from …

The human immunodeficiency virus–type 1 (HIV-1) envelope glycoproteins interact with
receptors on the target cell and mediate virus entry by fusing the viral and cell membranes …

The human immunodeficiency virus type 1 (HIV-1) envelope (Env) spike, comprising three
gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by …

Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …

Broadly neutralizing antibodies (bNAbs) to HIV-1 can prevent infection and are therefore of
great importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated …

A limiting factor in membrane protein research is the ability to solubilize and stabilize such
proteins. Detergents are used most often for solubilizing membrane proteins, but they are …

The entry of human immunodeficiency virus (HIV) into cells requires the sequential
interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and …

As the sole viral antigen on the HIV-1–virion surface, trimeric Env is a focus of vaccine
efforts. Here we present the structure of the ligand-free HIV-1–Env trimer, fix its conformation …

All previously characterized broadly neutralizing antibodies to the HIV-1 envelope
glycoprotein (Env) target one of four major sites of vulnerability. Here, we define and …

Antibodies to conserved epitopes on the human immunodeficiency virus (HIV) surface
protein gp140 can protect against infection in non-human primates, and some infected …